A pan-cancer bioinformatic analysis of the carcinogenic role of SMARCA1 in human carcinomas

PLoS One. 2022 Sep 20;17(9):e0274823. doi: 10.1371/journal.pone.0274823. eCollection 2022.

Abstract

SMARCA1is a mammalian imitation switch (ISWI) gene that encodes for SNF2L. SNF2L is involved in regulating cell transition from a committed progenitor state to a differentiated state. Although many papers have detailed the correlation between SMARCA1 and different cancers, no pan-cancer analysis has been conducted to date. We started by exploring the potential carcinogenic role of SMARCA1 across 33 carcinomas using the cancer genome atlas (TCGA) and the genotype-tissue expression (GTEx) databases. The expression of SMARCA1 was significantly elevated in some tumor types but not in others. There was a distinct relationship between SMARCA1 expression and patient prognosis. S116 phosphorylation levels were up-regulated in both lung adenocarcinoma and uterine corpus endometrial carcinoma. The expression level of SMARCA1 was positively correlated with cancer-associated fibroblasts infiltration in a number of tumors, such as colon adenocarcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma. It was also associated with CD8+ T-cell infiltration in head and neck squamous cell carcinoma and lung adenocarcinoma. Furthermore, SMARCA1 is involved in chromatin remodeling and protein processing-associated mechanisms. Our study presents an initial assessment and illustration of the carcinogenic role of SMARCA1 in different carcinomas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung*
  • Adenocarcinoma* / genetics
  • Carcinogenesis / genetics
  • Carcinogens
  • Colonic Neoplasms*
  • Computational Biology
  • DNA-Binding Proteins
  • Female
  • Humans
  • Transcription Factors / genetics
  • Uterine Cervical Neoplasms*

Substances

  • Carcinogens
  • DNA-Binding Proteins
  • SMARCA1 protein, human
  • Transcription Factors

Grants and funding

This study was supported by Ningbo Health Branding Subject Fund (PPXK2018-03).